Particularly, the study population exhibited a remarkably high baseline use of SGLT2 inhibitors (64.4%), a class known to improve vascular stiffness in patients with diabetes [42, 43], possibly influencing the null result for the primary CAVI endpoint. The gene discussed is SLC5A2; the disease is diabetes mellitus.